Beroni Group Limited

BTG

AU000000BTG8

Pharmaceuticals

End-of-day quote National Stock Exchange of Australia Other stock markets 06:00:00 2022-09-22 pm EDT			5-day change	1st Jan Change
3.96 ^AUD	-20.80%		-.--%	-.--%

Mar. 15	Beroni Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Beroni Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Beroni Group Limited (NSX:BTG) Enters into Convertible Loans

November 08, 2023 at 05:47 pm EST

Sydney, Australia, Nov 9, 2023 - (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into an unsecured and interest free convertible loan agreement with a group of investors for a principal loan amount of US$410,397.

The loan is convertible at US$1.00 per share (post-consolidation basis) upon listing of the Company's securities on the Nasdaq Stock Exchange or another US national securities exchange prior to the repayment date. The loan is repayable on 8 November 2024 unless converted earlier.

About Beroni Group Limited:

Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.

Contact:

T: +61-2-9159-1827
E: enquiry@beronigroup.com
W: www.beronigroup.com

Latest news about Beroni Group Limited

Beroni Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Beroni Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-13	CI
Beroni Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Beroni Group Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-13	CI
Beroni Group Limited Announces That It Has Received Notification from Its European Authorized Representative	22-06-01	CI
Beroni Group Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-01	CI
Beroni Group Limited Appoints John Chiplin to the Board of Directors	22-03-31	CI
Beroni Group Limited Sets Up a New R&D Centre in High-Tech Hub in Zhuhai, China	22-01-31	CI
Beroni Group Receives USD 1.07 Million Order for COVID-19 Antigen Test Kits from Japan	21-11-18	CI
Beroni Group Limited Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-10	CI
Beroni Group Receives Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAO	21-09-09	CI
Beroni Group Announces the Latest Clinical Study of its SARS-CoV-2 Antigen Test Kit	21-08-31	CI
Beroni Group Signs Mou with tella, Inc. to Collaborate in Immunotherapy for Cancer Treatment	21-05-28	CI
Beroni Group Limited announced that it has received $2 million in funding	21-05-27	CI
Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Has Received Export Permit	21-04-27	CI
Beroni Group Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-16	CI
Beroni Group Limited acquired unknown majority stake in PENAO Pty Ltd.	21-02-02	CI
Beroni Group’S Sars-COV-2 Antigen Test Kit Received CE Certification	20-12-21	CI
Beroni Group Launches a New Probiotics Health Product in China	20-11-10	CI
Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19	20-10-19	CI
Beroni Group Limited Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-11	CI
Beroni Group Receives First Commercial Order for Its COVID-19 Test Kits from Japan	20-09-08	CI
Beroni Group Has Successfully Constructed and Purified 24 Types of Nanobodies for Detection and Treatment of COVID-19	20-08-04	CI
Beroni Group Limited to Supply Covid-19 Antibody Test Kit to Japan	20-07-10	CI
Beroni Group Appoints Richard Buchta as Independent Non-Executive Director	20-06-30	CI

Chart Beroni Group Limited

Duration

Period

More charts

Company Profile

Beroni Group Limited is an Australia-based international biopharmaceutical company. The Company is engaged in the commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. It is engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. Its diversified portfolio is comprised of virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. It operates in Australia, United States, China and Japan. Its products offering include NicoBloc, CII-ArboViroPlex rRT-PCR assay and stem cell cosmetic products, including AGG Skin-Smoothing and Anti-Wrinkle Facial Mask, ODd Skin Repair Essence, ODd Beroni Beauty Facial Mask, and others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BERONI GROUP LIMITED	-.--%	52.52M
ELI LILLY AND COMPANY	+34.00%	664B
NOVO NORDISK A/S	+29.29%	567B
JOHNSON & JOHNSON	-7.75%	354B
MERCK & CO., INC.	+18.53%	330B
ABBVIE INC.	+4.95%	286B
ASTRAZENECA PLC	+13.79%	234B
NOVARTIS AG	+4.93%	199B
ROCHE HOLDING AG	-9.78%	196B
AMGEN INC.	-4.89%	148B